Arbutus Biopharma Corp’s recent filing unveils that its Director MANCHESTER KEITH S unloaded Company’s shares for reported $32637.0 on Aug 14 ’24. In the deal valued at $3.69 per share,8,846 shares were sold. As a result of this transaction, MANCHESTER KEITH S now holds 46,069 shares worth roughly $0.15 million.
Then, Sims Karen sold 4,358 shares, generating $10,078 in total proceeds. Upon selling the shares at $2.31, the Chief Medical Officer now owns 125,542 shares.
Before that, HASTINGS DAVID C sold 9,593 shares. Arbutus Biopharma Corp shares valued at $22,184 were divested by the Chief Financial Officer at a price of $2.31 per share. As a result of the transaction, HASTINGS DAVID C now holds 181,907 shares, worth roughly $0.58 million.
Jefferies upgraded its Arbutus Biopharma Corp [ABUS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late February with a ‘”a Hold”‘ rating. H.C. Wainwright began covering ABUS with “Buy” recommendation on December 17, 2020.
Price Performance Review of ABUS
On Tuesday, Arbutus Biopharma Corp [NASDAQ:ABUS] saw its stock fall -5.07% to $3.18. Over the last five days, the stock has lost -2.75%. Arbutus Biopharma Corp shares have fallen nearly -2.75% since the year began. Nevertheless, the stocks have risen 34.18% over the past one year. While a 52-week high of $4.72 was reached on 01/07/25, a 52-week low of $2.21 was recorded on 01/13/25. SMA at 50 days reached $3.50, while 200 days put it at $3.50.
Levels Of Support And Resistance For ABUS Stock
The 24-hour chart illustrates a support level at 3.11, which if violated will result in even more drops to 3.05. On the upside, there is a resistance level at 3.31. A further resistance level may holdings at 3.45. The Relative Strength Index (RSI) on the 14-day chart is 40.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.72%. Stochastics %K at 37.98% indicates the stock is a holding.
How much short interest is there in Arbutus Biopharma Corp?
A steep rise in short interest was recorded in Arbutus Biopharma Corp stocks on 2024-12-31, growing by 0.13 million shares to a total of 5.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 5.82 million shares. There was a rise of 2.14%, which implies that there is a positive sentiment for the stock.
